Form 4 for DXCM Dexcom
Accepted 2023-04-20 00:00:00 ET · period of report 2023-04-20 · accession 0001093557-23-000109 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-04-20 | 2023-04-20 | DXCM | Regan Barry J. | EVP Ops | S - Sale | $124.50 | -2,214 | 68.3K | -3% | -$275.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-20 | S | D | 2,214 | $124.50 | 68,258 | D | — | — | (F1) On November 1, 2022, Mr. Regan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Regan. The shares set forth above were sold pursuant to the 10b5-1 Plan. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. (F2) Included in this number are 62,232 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 6,684 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,416 of which were granted on November 19, 2020 and shall vest through November 19, 2024. |